Malaysia Liver Diseases Therapeutics Market Report 2022 to 2030

Malaysia Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Malaysia Liver Disease Therapeutics market will reach a value of $59 Mn from $37 Mn in 2022, growing at a CAGR of 5.9% during 2022-30. Liver Disease Therapeutics in Malaysia is dominated by a few domestic pharmaceutical companies such as Pharmaniaga, Kotra Pharma, and Hovid. The Liver Disease Therapeutics market in Malaysia is segmented into different types of disease and different therapy types. Some of the major factors affecting the Malaysia Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10MYPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Dr. Vishwa Modhia

Buy Now

Malaysia Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Malaysia Liver Disease Therapeutics market will reach a value of $59 Mn from $37 Mn in 2022, growing at a CAGR of 5.9% during 2022-30.

Malaysia, being an upper-middle-income, developing country, is a federation of 13 states and three federal territories in Southeast Asia. The Malaysian Liver Foundation (MLF) is the only national voluntary, non-profit, charitable organisation in Malaysia dedicated to the prevention, treatment and cure of liver, gallbladder and pancreatic illnesses through teaching, training and research.

Nevertheless, liver transplant activities in Malaysia remain low even if the brain-dead donor potential is considerable because of the regrettable high occurrence of multi-vehicle accidents. In terms of the Malaysian liver disease market, there are numerous pharmaceutical businesses that provide medications and treatments for liver illnesses. Gilead Sciences, AbbVie Inc., Bristol-Myers Squibb, and Roche are among the market's leading participants. According to the latest WHO data published in 2020 Liver Disease Deaths in Malaysia reached 5,125 or 3.05% of total deaths. The age-adjusted Death Rate is 17.91 per 100,000 of the population ranks Malaysia 97^th in the world. Malaysia's government spent 4.1% of its GDP on healthcare in 2020.

Malaysia Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

In Malaysia, liver disease is a major public health concern, with chronic hepatitis B and C being the predominant causes. The prevalence of chronic hepatitis B in Malaysia is believed to be approximately 3-5 %, whereas the prevalence of chronic hepatitis C is around 2.5 %. Both disorders can result in liver cirrhosis and cancer. A coalition of multi-disciplinary health specialists is being formed by medical experts to help prevent liver disease, a critical first step in Malaysia's larger fight against liver cancer. According to the Global Cancer Observatory, liver disease is the sixth most frequent cancer in Malaysia, with 2,149 new cases and 2,050 deaths documented in 2020. These aspects could boost Malaysia's Liver Disease Therapeutics market.

Market Restraints

There are few health facilities that provide services for liver illnesses such as liver transplants. At the moment, Selayang Hospital in West Malaysia is the only facility having an active dead donor liver transplantation programme. Malaysia's price competitiveness may suffer as a result of rising labour expenses, restricting the country's corporate activity. These factors may deter new entrants into the Malaysia Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Hovid: Hovid is a Malaysian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer, hepatitis B, and liver cirrhosis
Kotra Pharma: Kotra Pharma is a Malaysian pharmaceutical company that develops and produces a range of liver therapeutics, including drugs for the treatment of liver cancer and liver cirrhosis
Pharmaniaga: Pharmaniaga is a Malaysian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B
B. Braun: B. Braun is a global healthcare company that has a strong presence in Malaysia. The company produces a range of liver therapeutics, including drugs for the treatment of liver cancer and liver cirrhosis
Duopharma: Duopharma is a Malaysian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B

Recent Notable Updates

December 2022: Pharmaniaga LifeScience, a wholly-owned subsidiary of Pharmaniaga Berhad (Pharmaniaga), Malaysia's top pharmaceutical firm, has engaged in a research partnership agreement with BioNet-Asia for the development of a 6-in-1 Hexavalent Vaccine. The vaccine will give Malaysian healthcare practitioners the finest alternative for immunising children against six deadly childhood diseases. The initiative, which is in line with Pharmaniaga's plan to build the world's first Halal vaccine and insulin plants, will also help Malaysia achieve its goal of becoming vaccine self-sufficient by reducing Malaysia's reliance on importing essential lifesaving vaccines and insulins from outside Malaysia. In addition, the in-country manufacture of vaccines will considerably improve vaccine security against future pandemic risks.

Healthcare Policies and Reimbursement Scenarios

In Malaysia, the Drug Control Authority (DCA) is responsible for regulating the registration and approval of drugs, including those used for liver disease treatment. The DCA follows a strict regulatory framework that ensures the safety and efficacy of drugs. The Malaysian government provides reimbursement for some liver disease treatments, including hepatitis B and C. The reimbursement is available through the country's national healthcare insurance scheme, which covers most of the population.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.